Burden Of Disease Study Research Articles

Exploring Burden of Disease Metrics in EU legislation: A Systematic Analysis

Abstract Background The burden of disease (BoD) methodology is a valuable tool for evidence-based policymaking. However, there is currently no systematic analysis available regarding its use in the European Union (EU) legislation framework. This study aims to describe the implementation of BoD methodology in EU legislation. Methods A search was conducted on EUR-Lex, the official and most comprehensive platform to access EU legal documents. The main inclusion criteria in the analyses were date of publication (between 2004 and 2023, accounting for EU-25) and inclusion of BoD metrics (years of life lost - YLL, years lived with disability - YLD or disability-adjusted life years - DALY). Descriptive and network analysis were conducted to analyse the legislation content. Results Out of 2592 documents, 191 met the set criteria. Ten were legally binding, and 69% were published after 2018. The European Commission (n = 152) was the most regular issuing institution. BoD was mainly used as an argument (n = 93) and for impact assessment (n = 50). The metrics were commonly presented in the main text (n = 122) and in the annex (n = 48). EuroVoc domains like environment and social questions prevailed. The most frequent EuroVoc terms were climate change policy (n = 45), EU environmental policy (n = 32) and pollution control measures (n = 32). Discussion Despite the growing recognition of BoD metrics in supporting policymaking, only 191 documents published over the past 20 years within the EU legislation make reference to this methodology. Greater efforts in knowledge dissemination and directing research towards specific policy uptake may increase the application of BoD studies in EU policies. By advocating for increased awareness, promoting collaboration between researchers and policymakers, and targeting research efforts towards specific policy needs, a more comprehensive integration of BoD methodologies into EU legislation can be achieved, contributing for evidence-informed policies. Key messages • There were only 191 documents of the EU legislative documents published in the past 20 years mention burden of disease metrics, mainly addressing environmental and social issues. • There is a need to increase EU policy uptake from BoD studies, by conducting policy-oriented research, and building capacity among researchers and policymakers on BoD methodology.

Improving transparency: Development of reporting guidelines for burden of disease studies

Abstract The burden of disease (BOD) approach, originating with the Global Burden of Disease (GBD) study in the 1990s, has become a cornerstone for population health monitoring. Despite the widespread use of the Disability-Adjusted Life Year (DALY) metric, variations in methodological approaches and reporting inconsistencies hinder comparability across studies. To tackle this issue, we set out to develop guidelines for reporting DALY calculation studies to improve the transparency and comparability of BOD estimates. The development of the STROBOD statement began within the European Burden of Disease Network, evolving from initial concepts discussed in workshops and training sessions focused on critical analysis of BOD studies. In 2021, a working group was formed to refine the preliminary version into the final Standardised Reporting of Burden of Disease studies (STROBOD) statement, consisting of 28 items structured across six main sections. These sections cover the title, abstract, introduction, methods, results, discussion, and open science, aiming to ensure transparency and standardization in reporting BOD studies. Notably, the methods section of the STROBOD checklist encompasses aspects such as study setting, data inputs and adjustments, DALY calculation methods, uncertainty analyses, and recommendations for reproducibility and transparency. A pilot phase was conducted to test the efficacy of the STROBOD statement, highlighting the importance of providing clear explanations and examples for each reporting item. The inaugural STROBOD statement offers a crucial framework for standardizing reporting in BOD research, with plans for ongoing evaluation and potential revisions based on user feedback. While the current version focuses on general BOD methodology, future iterations may include specialized checklists for distinct applications such as injury or risk factor estimation, reflecting the dynamic nature of this field.

Developing survey instruments for low back and neck pain to improve disease severity estimates for burden of disease assessment

Abstract Two people living with the same disease can have very different experiences; one has little consequence, whilst the other struggles with much more debilitating consequences that impacts how they live their lives day-to-day. A growing body of research highlights the need for better estimates of disease severity to facilitate better estimation of the non-fatal burden of disease (BOD). Routine data does not always offer solutions because it’s often not coded at a granular enough level to map to individual health states. Data offering solutions are scarce and therefore not available across time or space. Most commentators have quantified the problem of assuming the same proportional severity splits to fill data gaps; a problem common to the Global Burden of Disease (GBD) study and independent BOD studies. However, whilst the need for highlighting the problems associated with this assumption remains, there are other positive steps that can be taken to overcome it. We propose how reproducible approaches can be developed, and present how they can be used to develop disease severity estimates. This involves developing a survey instrument to estimate the overall and health state prevalence of back pain and neck pain, basing health state definitions from the GBD non-fatal disease models, where the classification of cases by severity is based on the combination of respondent’s answers. Furthermore, we discuss how self-assessed severity estimates allow for internal validity checks, but also more widely offer opportunities to appraise the appropriateness of GBD non-fatal disease models. The development, and publication, of survey instruments can assist both independent studies and the GBD study to improve estimates of disease severity, as well as retaining important opportunities for cross-country comparability. Understanding the spectrum of severity is important for understanding how disease impacts populations and can inform healthcare provision and expenditure strategies.

Reception of health data using the Australian Burden of Disease study as an example

Abstract Background Health data, especially on Burden of Disease (BoD), are vital for evidence-based health promotion and effective dissemination is crucial due to resource intensiveness. Germany’s national BoD study is currently transitioning to permanence. Analysing the Australian Institute of Health and Welfare’s (AIHW) well-established collaboration with stakeholders and their reception of health data at national and regional level offers insights for improved knowledge translation. Methods To follow the path of stakeholder engagement, this 3-month project involved scientific exchanges with the AIHW and Department of Health, Western Australia. It compiled communication strategy examples and documents stating examples of BoD data use. A quantitative online survey accompanied by a series of 18 qualitative 45-minute interviews was conducted. The survey implemented via Swift Digital has been running for 20+ days. Interview partners originated from the fields of health research, politics, planning and advocacy for patients or population groups. Results were analysed, illustrated digitally as a booklet and refined in a participatory workshop. Results Communication strategies such as embargoed press and stakeholder releases as well as regular online formats were identified. The survey and interviews displayed the required technical and content-detail level from key facts to raw data and visualisation needs. Noteworthy are the demand to link data to economic aspects like disease expenditure, trends and future scenarios. It elucidated how diverse target groups utilize data to place disease significance and preventive public health measures, aiding dissemination. Alongside, it shows examples of knowledge translation by emphasizing impact over indicators when targeting communities. Conclusions Prioritizing target group identification and employing tailored communication strategies regarding data format and detail level are essential when utilizing new data. Key messages • Analyzing a well-established collaboration with stakeholders offers insights for improved knowledge translation and reveals leveraging engagement strategies for others. • Understanding stakeholder needs is essential for promoting broader health data use in policy and practice, fostering evidence-based decision-making, and enhancing public health outcomes.

Standardised reporting of burden of disease studies: the STROBOD statement.

The burden of disease (BOD) approach, originating with the Global Burden of Disease (GBD) study in the 1990s, has become a cornerstone for population health monitoring. Despite the widespread use of the Disability-Adjusted Life Year (DALY) metric, variations in methodological approaches and reporting inconsistencies hinder comparability across studies. To tackle this issue, we set out to develop guidelines for reporting DALY calculation studies to improve the transparency and comparability of BOD estimates. The development of the STROBOD statement began within the European Burden of Disease Network, evolving from initial concepts discussed in workshops and training sessions focused on critical analysis of BOD studies. In 2021, a working group was formed to refine the preliminary version into the final Standardised Reporting of Burden of Disease studies (STROBOD) statement, consisting of 28 items structured across six main sections. These sections cover the title, abstract, introduction, methods, results, discussion, and open science, aiming to ensure transparency and standardization in reporting BOD studies. Notably, the methods section of the STROBOD checklist encompasses aspects such as study setting, data inputs and adjustments, DALY calculation methods, uncertainty analyses, and recommendations for reproducibility and transparency. A pilot phase was conducted to test the efficacy of the STROBOD statement, highlighting the importance of providing clear explanations and examples for each reporting item. The inaugural STROBOD statement offers a crucial framework for standardizing reporting in BOD research, with plans for ongoing evaluation and potential revisions based on user feedback. While the current version focuses on general BOD methodology, future iterations may include specialized checklists for distinct applications such as injury or risk factor estimation, reflecting the dynamic nature of this field.

Burden of disease studies supporting policymaking in the European Union: a systematic review.

Burden of disease (BoD) studies quantify the health impact of diseases and risk factors, which can support policymaking, particularly in the European Union (EU). This study aims to systematically analyse BoD studies, which address EU public policies to contribute to the understanding of its policy uptake. A systematic search of six electronic databases and two grey-literature registries was carried out for articles published between 1990 and 2023. The thematic area, type of legislation and the respective policymaking stage were extracted. A textual analysis of the discussion was conducted to assess the inclusion of specific EU policy implications. Overton was used to detect citations in policy documents. Out of the 2054 records screened, 83 were included. Most studies employed secondary data, with 37 utilizing GBD data. Disability-adjusted life year was present in most of the studies (n = 53). The most common type of the EU legislation mentioned was the directive (n = 47), and the most frequent topic was environment (n = 34). Policy implications for EU laws were discussed in most papers (n = 46, 55.4%), with only 8 conducting evaluation of EU policies. Forty-two articles have been cited at the EU-level, in a total of 86 EU policies. Despite increasing efforts in integrating EU legislation impact within BoD studies, these results denote a low consideration of the legal and policy changes. Greater efforts in directing research towards policy effectiveness evaluation might increase their uptake in EU policies.

Improving the spatial and temporal resolution of burden of disease measures with Bayesian models

This paper contributes to the field by addressing the critical issue of enhancing the spatial and temporal resolution of health data. Although Bayesian methods are frequently employed to address this challenge in various disciplines, the application of Bayesian spatio-temporal models to burden of disease (BOD) studies remains limited. Our novelty lies in the exploration of two existing Bayesian models that we show to be applicable to a wide range of BOD data, including mortality and prevalence, thereby providing evidence to support the adoption of Bayesian modeling in full BOD studies in the future. We illustrate the benefits of Bayesian modeling with an Australian case study involving asthma and coronary heart disease. Our results showcase the effectiveness of Bayesian approaches in increasing the number of small areas for which results are available and improving the reliability and stability of the results compared to using data directly from surveys or administrative sources.

Postpandemic Sentinel Surveillance of Respiratory Diseases in the Context of the World Health Organization Mosaic Framework: Protocol for a Development and Evaluation Study Involving the English Primary Care Network 2023-2024.

Prepandemic sentinel surveillance focused on improved management of winter pressures, with influenza-like illness (ILI) being the key clinical indicator. The World Health Organization (WHO) global standards for influenza surveillance include monitoring acute respiratory infection (ARI) and ILI. The WHO's mosaic framework recommends that the surveillance strategies of countries include the virological monitoring of respiratory viruses with pandemic potential such as influenza. The Oxford-Royal College of General Practitioner Research and Surveillance Centre (RSC) in collaboration with the UK Health Security Agency (UKHSA) has provided sentinel surveillance since 1967, including virology since 1993. We aim to describe the RSC's plans for sentinel surveillance in the 2023-2024 season and evaluate these plans against the WHO mosaic framework. Our approach, which includes patient and public involvement, contributes to surveillance objectives across all 3 domains of the mosaic framework. We will generate an ARI phenotype to enable reporting of this indicator in addition to ILI. These data will support UKHSA's sentinel surveillance, including vaccine effectiveness and burden of disease studies. The panel of virology tests analyzed in UKHSA's reference laboratory will remain unchanged, with additional plans for point-of-care testing, pneumococcus testing, and asymptomatic screening. Our sampling framework for serological surveillance will provide greater representativeness and more samples from younger people. We will create a biomedical resource that enables linkage between clinical data held in the RSC and virology data, including sequencing data, held by the UKHSA. We describe the governance framework for the RSC. We are co-designing our communication about data sharing and sampling, contextualized by the mosaic framework, with national and general practice patient and public involvement groups. We present our ARI digital phenotype and the key data RSC network members are requested to include in computerized medical records. We will share data with the UKHSA to report vaccine effectiveness for COVID-19 and influenza, assess the disease burden of respiratory syncytial virus, and perform syndromic surveillance. Virological surveillance will include COVID-19, influenza, respiratory syncytial virus, and other common respiratory viruses. We plan to pilot point-of-care testing for group A streptococcus, urine tests for pneumococcus, and asymptomatic testing. We will integrate test requests and results with the laboratory-computerized medical record system. A biomedical resource will enable research linking clinical data to virology data. The legal basis for the RSC's pseudonymized data extract is The Health Service (Control of Patient Information) Regulations 2002, and all nonsurveillance uses require research ethics approval. The RSC extended its surveillance activities to meet more but not all of the mosaic framework's objectives. We have introduced an ARI indicator. We seek to expand our surveillance scope and could do more around transmissibility and the benefits and risks of nonvaccine therapies.

10.F. Workshop: Projecting future burden of disease for informed public health decision making

Abstract What are the most relevant diseases in a country? As the need for prioritising the use of available resources constantly increases, a timely, sound and comprehensive answer to this question is more than ever needed to inform public health decision making. The burden of disease metrics such as the Disability-adjusted Life Years (DALY) are important indicators for health information. The DALY provides a comprehensive indicator of the health gap in a country, addressing both premature mortality and health loss due to the occurrence of diseases. The European Burden of Disease Network (COST Action CA18218) acts as a technical platform for integrating and strengthening capacity in burden of disease assessment across Europe and beyond. The Action places a key focus on identifying and addressing data challenges, methodological choices and the need for translating research into policy. Where many Burden of disease (BoD) studies aim at producing the best estimates for the recent years, some countries are also making future projections of DALYs. By doing so, BoD studies become even more relevant for the policy making process since the do not cover only current best estimates, but also show what policy makers might be anticipating on. There are different methods to make future projections, varying from trend extrapolations and forecasts to developing scenarios as part of and advanced foresight approach. Future projections of the DALY estimates bring along additional data requirements. To be able to calculate future DALYs, projections of prevalence and causes of death, but also of population demographics, are needed. In addition, methodological choices have to be made to calculate future DALYs, for example regarding life tables. In this workshop, all these aspects will be addressed. Several countries (i.e. The Netherlands, Belgium, Scotland and Norway) will present their approaches to estimate future DALYs. The workshop will start with and interactive Mentimeter session to get a better view on how the audience is familiar with (future) Burden of Disease. Then, a brief presentation is given as introduction to the European Burden of Disease Network. This is followed by the four presentations of future DALYs. The workshop will be concluded by a discussion with the presenters on the lessons learned regarding their experience of doing future projections. Key messages • Burden of disease becomes even more relevant for policy makers when projections are included in the Burden of Disease study. • Data and methodological issues should be properly addressed to better inform policy makers.

Harmonized approach to estimate the burden of disease of dietary exposure to four chemical contaminants - A French study

Exposure to chemical contaminants found in foods has been associated with various adverse health effects. Burden of disease studies are increasingly used to estimate the public health impact of such exposures. The aims of this study were to estimate the burden of disease due to dietary exposure to four chemicals in France in 2019 (lead (Pb), cadmium (Cd), methylmercury (MeHg), and inorganic arsenic (i-As)), and to develop harmonized methods that can be applied for other chemicals and countries. We used national food consumption data from the third French national food consumption survey, chemical food monitoring data from the Second French Total Diet Study (TDS), dose-response data and disability weights from scientific literature, and disease incidence and demographics from national statistics. We adopted a risk assessment approach to estimate disease burden, incidence, mortality, and Disability-Adjusted Life Years (DALYs) attributable to dietary exposure to the chemicals. In all models, we harmonized food classification and exposure assessment. We propagated uncertainty through the calculations using Monte Carlo simulation. We estimated that, among these chemicals, i-As and Pb were responsible for the highest disease burden. i-As was estimated to cause 820 DALYs, or approximately 1.25 DALYs per 100,000 inhabitants. The estimated burden of Pb was 1834 to 5936 DALYs, or 2.7 (lower bound) to 8.96 (upper bound) DALYs/100,000. The burden of MeHg (192 DALYs), and Cd (0 DALY) was substantially lower. The foods contributing most to disease burden was drinks (30 %), “other foods” (mostly composite dishes) (19 %), and fish and seafood (7 %). Interpretation of estimates needs to consider all underlying uncertainties, linked with data and knowledge gaps. The harmonized models are the first to make use of data from TDS, which are available in several other countries. Thus, they can be applied to estimate the burden and to rank food-associated chemicals at national level.

Reflections on burden of disease and health impact assessment methods for noise

Burden of Disease (BoD) assesses the noise impact on health at a given time and in a given population, whereas Health Impact Assessments (HIA) are conducted in the frame of decision-making to evaluate health effects of a policy, programme or project. In a 2020 report, the European Environmental Agency estimates transportation noise exposure in Europe annually results in 22 million highly annoyed, 6.5 million highly sleep disturbed, 48,000 cases of ischemic heart diseases and 12,000 deaths, and 12,400 children with cognitive impairments. These are based on END exposure assessment and exposure-response functions from the WHO noise guidelines 2018. Many more regional or national HIA and BoD studies have been conducted, and common methods across future assessments for consistent communication are needed. Given the rapid developments in noise research, current BoD and HIA are also partly outdated. Critical methodological issues will be discussed using national and regional examples with a focus on Switzerland. This includes the selection of noise sources, relevant health outcomes and corresponding exposure-response functions. Derivation of the lowest effect noise threshold, potential double-counting, and communication of results are also discussed with the aim toward a common understanding for the conduct of future BoD and HIA.

Quality of life and societal costs in hypertrophic cardiomyopathy: protocol of the AFFECT-HCM study.

Ever since the first description of hypertrophic cardiomyopathy (HCM), the most common genetic cardiac disease, tremendous progress has been made in the evaluation and management of HCM patients, but little attention has been focused on the impact of HCM on societal costs and quality of life (QoL). This paper describes the study protocol for the AFFECT-HCM study into burden of disease (BoD), which aims to estimate health-related QoL and societal costs in HCM patients and genotype-positive phenotype-negative (G+/P-) relatives during aone-year follow-up study, and relate this to the phenotypical HCM expression. Atotal of 400 Dutch HCM patients and 100 G+/P- subjects will be followed for one year in aprospective, multi-centre, prevalence-based BoD study. Societal costs will be measured via abottom-up approach using the cost questionnaires iMCQ and iPCQ. For QoL, the generic EQ-5D-5L and disease-specific Kansas City Cardiomyopathy Questionnaire will be used. QoL and societal costs will be compared with phenotype-specific HCM characteristics and other determinants to identify factors that influence BoD. Accelerometry will test the correlation between BoD and physical activity. The AFFECT-HCM study will evaluate the BoD in HCM patients and G+/P- subjects to improve the understanding of the societal and economic impact of HCM.

Conducting national burden of disease studies and knowledge translation in eight small European states: challenges and opportunities

BackgroundSeveral countries across Europe are engaging in burden of disease (BoD) studies. This article aims to understand the experiences of eight small European states in relation to their research opportunities and challenges in conducting national BoD studies and in knowledge translation of research outputs to policy-making.MethodsCountries participating in the study were those outlined by the WHO/Europe Small Countries Initiative and members of the Cooperation in Science and Technology (COST) Action CA18218 European Burden of Disease Network. A set of key questions targeting the research landscape were distributed to these members. WHO’s framework approach for research development capacities was applied to gain a comprehensive understanding of shortages in relation to national BoD studies in order to help strengthen health research capacities in the small states of Europe.ResultsMost small states lack the resources and expertise to conduct BoD studies, but nationally representative data are relatively accessible. Public health officials and researchers tend to have a close-knit relationship with the governing body and policy-makers. The major challenge faced by small states is in knowledge generation and transfer rather than knowledge translation. Nevertheless, some policy-makers fail to make adequate use of knowledge translation.ConclusionsSmall states, if equipped with adequate resources, may have the capacity to conduct national BoD studies. This work can serve as a model for identifying current gaps and opportunities in each of the eight small European countries, as well as a guide for translating country BoD study results into health policy.

Reporting guidelines for burden of disease studies: why and how?

Abstract Background The Disability Adjusted Life Year (DALY) is a frequently used metric to assess burden of disease (BoD). Many independent BoD studies have been performed across Europe, showing wide variations and inconsistencies in the application and reporting of DALY specific methods. The European Burden of Disease Network (burden-eu) aims to develop guidelines for reporting DALY calculation studies which may enhance transparency and comparability of BoD estimates across Europe and beyond. Methods A burden-eu working group of experts generated a list of potential reporting items based on existing literature, guidance for developing guidelines and consultations with BoD experts. To pilot the drafted product, we asked BoD experts and non-experts to apply it to existing BoD studies. We received feedback and we revised the guidelines accordingly. Results The guide for DALY calculation studies comprises about 25 items that should be reported in BoD studies. We included information about the study setting, data input sources including methods for data corrections, DALY-specific methods (e.g., YLL life table, YLD approach, disability weights etc), data analyses, and data limitations. We also included information on how users can compare their new estimates with previously available BoD estimates. Conclusions We introduced a reporting instrument for DALY calculations that can be used to document input data and methodological design choices in BoD studies. The application of such guidelines will enhance usability of BoD estimates for decision-makers as well as global, regional, and national health experts. Key messages

9.Q. Skills building seminar: Redistribution of ill-defined deaths: a methodological conundrum

Abstract Today, several countries are conducting national burden of disease (BOD) studies, calculating Disability-Adjusted Life Years (DALYs) for a variety of diseases, injuries and risk factors. The DALY metric is composed of a morbidity component, the Years Lived with Disability (YLDs), and a mortality component, the Years of Life Lost (YLLs). The calculation of YLLs typically starts from national cause of death data, which are coded using the International Statistical Classification of Diseases and Related Health Problems (ICD). National BOD studies however often follow (a modified version of) the cause hierarchy of the Global Burden of Disease (GBD) study, which applies coarser categories, and does not contain unknown or ill-defined causes. This implies that not all ICD codes can be mapped to one specific BOD cause, giving rise to so-called “ill-defined” or “garbage” codes. To include all deaths in a national BOD study, it is therefore necessary to redistribute the ill-defined deaths to specific BOD causes. Several methodological approaches exist for redistribution of ill-defined deaths, ranging from the use of fixed redistribution proportions to advanced redistribution algorithms based on multiple cause of death data. The choice of the methodology needs to depend on the nature of the available cause of death data, and as a consequence, methodologies are typically tailored to the specific data at hand. The absence of a single best methodology, and the methodological heterogeneity across applications, has made redistribution of ill-defined deaths into a methodological conundrum. This skills building workshop will present the redistribution methods applied in different national burden of disease studies, including a discussion of their strengths and weaknesses. By providing a step-by-step presentation of how the methods have been applied, attendees will gain unique insights in the different redistribution methods currently applied. Key messages • Redistribution of ill-defined deaths is an essential part of national burden of disease studies, but is methodologically challenging. • Attendees will receive an overview of the redistribution methods applied in different national burden of disease studies, including a discussion of their strengths and weaknesses.

The global burden of neglected zoonotic diseases: current state of evidence

Abstract The majority of emerging infectious diseases are zoonoses, most of which are classified as “neglected”. By affecting both humans and animals, zoonoses pose a dual burden. The disability-adjusted life year (DALY) metric quantifies human health burden using mortality and morbidity. This review aims to describe and analyze the current state of evidence on the burden of neglected zoonotic diseases (NZDs) and start a discussion on the current understanding of the global burden of NZDs. We identified 26 priority NZDs through consulting the CDC One Health Zoonotic Disease Prioritization Exercise, the Joint External Evaluation reports, and the WHO roadmap for NTDs. A systematic review of global and national burden of disease (BoD) studies for these priority NZDs was conducted using pre-selected databases. Data on diseases, location and DALYs were extracted for each eligible study. A total of 1887 records were screened, resulting in 72 eligible studies (58 national or sub-national, 12 global, and 2 regional studies). The highest number of BoD studies was found for non-typhoidal salmonellosis (23), whereas no estimates were found for West Nile, Marburg and Lassa fever. Geographically, the highest number of studies were found in the Netherlands (11), China (5) and Iran (4). The number of BoD studies retrieved mismatched the perceived importance in national prioritization exercises. For example, anthrax was considered a priority NZD in 73 countries, but only one national estimate was retrieved. By summing the available global estimates, these diseases would cause at least 10 million DALYs in total. The burden of NZDs at the global level remains scattered, and trends were challenging to identify. There are several priority NZDs for which no burden estimates exist, and the number of BoD studies does not reflect national disease priorities. To have complete and consistent estimates of the global burden of NZDs, these diseases should be integrated into larger global BoD initiatives. Key messages • There is a mismatched between the estimated retrieved in the search and the perception of the importance of these disease. This amplify the need for a comprehensive program. • No complete list of zoonoses exist, and the definition used is vague. A stricter definition of zoonoses and what defines them will help provide a clear view of dealing with and controlling them.

Burden of disease assessment for Germany and its regions – results from the BURDEN 2020 study

Abstract Background Epidemiological measures such as incidence, prevalence, or deaths are essential for monitoring population health. However, evaluating them in isolation cannot adequately compare and assess the relative importance of different diseases. Assessments of the burden of disease (BoD) are therefore of growing importance in supporting health policy decisions. Using disability-adjusted life years (DALY) as a summary measure of population health, BoD integrates morbidity and mortality in a transparent approach. Methods Within BoD methodology, deviations in the health of the population from an ‘ideal’ health status is quantified in the unit of life years. DALY are the sum of years of life lost due to death (YLL) and years lived with disability (YLD). While YLL describe the gap between age at death and statistical life expectancy, the indicator YLD quantifies years lived with a disability or disease. Calculations were based on different primary and secondary data sources for Germany, especially cause-of-death statistics, epidemiological survey data, and statutory health insurance data. Results In Germany, there were about 12 million DALY in 2017, the equivalent of 14,584 DALY per 100,000 population. Coronary heart disease contributes the most to the overall burden of disease, followed by lower back pain and lung cancer. In women, headache disorders and dementias account for more DALY as compared to men. Men have a higher burden of disease from lung cancer or alcohol use disorders. Pain disorders and alcohol use disorders lead the DALY rankings for both sexes in younger adulthood. The burden due to cardiovascular disease, COPD, and diabetes mellitus increases with age and also varies by region. Conclusions The results suggest age- and gender-specific prevention as well as regional health care needs. BoD studies therefore provide comprehensive data for population health surveillance and can support health policy decisions. Key messages • The importance of specific diseases as measured by DALY differs greatly by age and gender, highlighting the need for targeted prevention measures. • Regional patterns emerge for cardiovascular disease, COPD, and depressive disorders, among others, which may indicate health care needs.

Methodological considerations in injury burden of disease studies across Europe: a systematic literature review

BackgroundCalculating the disease burden due to injury is complex, as it requires many methodological choices. Until now, an overview of the methodological design choices that have been made in burden of disease (BoD) studies in injury populations is not available. The aim of this systematic literature review was to identify existing injury BoD studies undertaken across Europe and to comprehensively review the methodological design choices and assumption parameters that have been made to calculate years of life lost (YLL) and years lived with disability (YLD) in these studies.MethodsWe searched EMBASE, MEDLINE, Cochrane Central, Google Scholar, and Web of Science, and the grey literature supplemented by handsearching, for BoD studies. We included injury BoD studies that quantified the BoD expressed in YLL, YLD, and disability-adjusted life years (DALY) in countries within the European Region between early-1990 and mid-2021.ResultsWe retrieved 2,914 results of which 48 performed an injury-specific BoD assessment. Single-country independent and Global Burden of Disease (GBD)-linked injury BoD studies were performed in 11 European countries. Approximately 79% of injury BoD studies reported the BoD by external cause-of-injury. Most independent studies used the incidence-based approach to calculate YLDs. About half of the injury disease burden studies applied disability weights (DWs) developed by the GBD study. Almost all independent injury studies have determined YLL using national life tables.ConclusionsConsiderable methodological variation across independent injury BoD assessments was observed; differences were mainly apparent in the design choices and assumption parameters towards injury YLD calculations, implementation of DWs, and the choice of life table for YLL calculations. Development and use of guidelines for performing and reporting of injury BoD studies is crucial to enhance transparency and comparability of injury BoD estimates across Europe and beyond.

Global and national burden and trends of mortality and disability-adjusted life years for silicosis, from 1990 to 2019: results from the Global Burden of Disease study 2019

BackgroundSilicosis, as an important type of pneumoconiosis, leads to progressive and irreversible conditions from the beginning of inflammation and fibrosis. However, the data on the global burden of silicosis and long-term trends were limited.MethodsDerived from the Global Burden of Disease study 2019 (online publicly available: Global Health Data Exchange), data on both crude and age-standardized rates (ASR) per 100,00 people of mortality and disability-adjusted life years (DALYs) due to silicosis was collected and analyzed. The burden and trends of mortality and DALYs due to silicosis was assessed by 204 countries and territories, by 5-year interval of age group and by sex from 1990 to 2019. And all the regions were divided into 5 categories according to Sociodemographic Index (SDI). Temporal trends in mortality and DALY were evaluated only to ASR by the Joinpoint regression model.ResultsMore than 12.9 thousand [95% Uncertainty Intervals (UI): 10.9, 16.2] death cases occurred due to silicosis worldwide, and 655.7 thousand (95% UI: 519.3, 828.0) DALYs were attributed to silicosis in 2019. From 1990 to 2019, global number of mortality and DALYs in countries with high SDI quintile decreased by 0.35% (95% UI: − 0.45, − 0.17) and 0.32% (95% UI: − 0.45, − 0.01), respectively. There was a greater burden in low- and middle-income countries were estimated in 2019 according to ASRs. The global number of mortality and DALYs among males accounted for over 95% of all in 2019. Both age-sex-specific mortality and DALY rate were increasing with aging and reached their peak at 85–89 age group. During the past 30 years, ASR of mortality and DALYs showed a decreasing trend with average annual percentage change at -3.0% [95% Confidence Intervals (CI): − 3.2, − 2.9] and − 2.0 (95% CI: − 1.7, − 2.2), respectively.ConclusionsSilicosis remains an important health issue and causes a potentially serious burden worldwide. Attention should be paid to making preventable, affordable and effective measures in lower SDI regions.

Trends and Disparities in the Incidence of Intraocular Foreign Bodies 1990-2019: A Global Analysis.

ObjectivesThis study aims to provide trends and disparities in the incidence of intraocular foreign bodies (IOFBs) from 1990 to 2019 in 204 countries by region, country, socio-demographic index (SDI), age, and sex.MethodsThe global, regional and national number of incident cases as well as age-standardized incidence rate (ASIR) of IOFBs were attained from the Global Burden of Disease Study 2019 (GBD 2019). To estimate the trend of ASIR of IOFBs, the estimated annual percentage change (EAPC) was calculated from 1990 to 2019.ResultsGlobally, although ASIR of IOFBs decreased with an EAPC of −0.93% [95% uncertainty interval (UI) −1.1 to −0.76] from 1990 to 2019, ASIR of IOFBs increased from 2008 to 2019. From 35.79 million (95% UI 23.62–50.89) in 1990 to 46.63 million (95% UI 32.45–64.45) in 2019, the number of IOFB incident cases worldwide increased by 30.29% (95% UI 19.63–43.55). The incidence of IOFBs varied by region and country, and it was closely related to socio-economic development. Furthermore, while ASIR of IOFBs was high in the young population aged 15–49 years, we observed a significant increase in the number of IOFB incident cases in older adults when compared to other age groups. In terms of sex, males accounted for the vast majority of IOFB incident cases.ConclusionsThe global ASIR of IOFBs is on the rise, with an increase in incident cases, designating IOFBs as a global health challenge. The incidence of IOFBs cases is directly related to geographic location, socio-economic status, age, sex, and other factors. Our findings could be useful for the control and prevention of IOFBs.